Table 3.
SA-2: patient characteristics of the subgroup with clinical response recorded
| Patient characteristics before PSW | Patient characteristics (%) after PSWa | |||||
|---|---|---|---|---|---|---|
| CCT (n = 79) | Without CCT (n = 167) | Standardized differenceb | CCT | Without CCT | Standardized differenceb | |
| Number (%)b or mean (SD)b | Number (%)b or mean (SD)b | |||||
| Age (years) | ||||||
| ≤ 58 | 42 (53) | 90 (54) | 0.015 | 51 | 51 | ≈ 0 |
| > 58 | 37 (47) | 77 (46) | 49 | 49 | ||
| Gender | ||||||
| Female | 4 (5) | 7 (4) | 0.042 | 5 | 5 | ≈ 0 |
| Male | 75 (95) | 160 (96) | 95 | 95 | ||
| Residency | ||||||
| Non-north | 60 (76) | 119 (71) | 0.107 | 74 | 74 | ≈ 0 |
| North | 19 (24) | 48 (29) | 26 | 26 | ||
| Comorbidity | ||||||
| Without | 69 (87) | 146 (87) | 0.003 | 88 | 88 | ≈ 0 |
| Withc | 10 (13) | 21 (13) | 12 | 12 | ||
| BMI (kg/m2) | ||||||
| ≤ 18.5 | 15 (19) | 36 (22) | 0.064 | 19 | 19 | ≈ 0 |
| > 18.5 | 64 (81) | 131 (78) | 81 | 81 | ||
| Drinking | ||||||
| No | 11 (14) | 22 (13) | 0.022 | 14 | 14 | ≈ 0 |
| Yes | 68 (86) | 145 (87) | 86 | 86 | ||
| Smoking | ||||||
| No | 8 (10) | 20 (12) | 0.059 | 11 | 11 | ≈ 0 |
| Yes | 71 (90) | 147 (88) | 89 | 89 | ||
| Grade | ||||||
| Poorly | 25 (32) | 40 (24) | 0.172 | 31 | 31 | ≈ 0 |
| Well/moderately differentiated | 54 (68) | 127 (76) | 69 | 69 | ||
| Tumor location | ||||||
| Upper | 43 (54) | 65 (39) | 50 | 50 | ||
| Middle | 25 (32) | 75 (45) | 0.275 | 35 | 35 | ≈ 0 |
| Lower | 11 (14) | 27 (16) | 0.063 | 15 | 15 | ≈ 0 |
| Tumor size (cm) | ||||||
| ≤ 5 cm | 34 (43) | 61 (37) | 0.133 | 43 | 43 | ≈ 0 |
| > 5 cm | 45 (57) | 106 (63) | 57 | 57 | ||
| Clinical T-stage | ||||||
| T1–T2 | 7 (9) | 17 (10) | 0.045 | 8 | 8 | ≈ 0 |
| T3–T4 | 72 (91) | 150 (90) | 92 | 92 | ||
| Clinical N-stage | ||||||
| N0 | 7 (9) | 8 (5) | 0.162 | 7 | 7 | ≈ 0 |
| N1–N2 | 72 (91) | 159 (95) | 93 | 93 | ||
| Clinical stage | ||||||
| II | 9 (11) | 14 (8) | 0.101 | 10 | 10 | ≈ 0 |
| III | 70 (89) | 153 (92) | 90 | 90 | ||
| Reason for no surgery | ||||||
| Without contraindication | 75 (95) | 154 (92) | 0.111 | 94 | 94 | ≈ 0 |
| With contraindication | 4 (5) | 13 (8) | 6 | 6 | ||
| RT modality | ||||||
| 3DCRT | 7 (9) | 4 (2) | 0.283 | 5 | 5 | ≈ 0 |
| IMRT | 72 (91) | 163 (98) | 95 | 95 | ||
| Use of PET | ||||||
| No | 34 (43) | 42 (25) | 0.384 | 35 | 35 | ≈ 0 |
| Yes | 45 (57) | 125 (75) | 65 | 65 | ||
| RT break | ||||||
| ≤ 1 week | 63 (80) | 125 (75) | 0.117 | 79 | 79 | ≈ 0 |
| > 1 week | 16 (20) | 42 (25) | 21 | 21 | ||
| RT dose | ||||||
| Low | 19 (24) | 54 (32) | 0.185 | 26 | 26 | ≈ 0 |
| High | 60 (76) | 113 (68) | 74 | 74 | ||
| Induction chemotherapy | ||||||
| Without | 74 (94) | 162 (97) | 0.159 | 95 | 95 | ≈ 0 |
| With | 5 (6) | 5 (3) | 5 | 5 | ||
3DCRT, three-dimensional radiotherapy; BMI, Body Mass Index; CCT, consolidative chemotherapy; IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiotherapy; PET, positron emission tomography; PSW, propensity score weighting; RT, radiotherapy; SD, standard deviation
aWeighted proportion for each group
bRounded
cModified Carlson comorbidity score ≥ 1